Broad Institute Posters

Sunday, April 2nd 2017

1:00pm - 5:00pm

 Session PO.BSB01.01 Bioinformatics and Analysis for Therapy and Immune System

Computational analysis of clinically actionable genomic features: precision heuristics for interpreting the alteration landscape (PHIAL)

B. Reardon, N. Moore, E. Van Allen

Presentation 558/19

 

Oncovirus detection and integration analysis from human tumor samples using targeted massively parallel sequencing

R.T. Burns, S.S. Hunter, M.D. Ducar, A.R. Thorner, J.A.Decaprio, P. Van Hummelen, A. Frieden, A. Nag, H.A. Coleman, M.K. Slevin, A. Clapp, S.D. Drinan, S.R. McShane, E. Thai, P. Shivdasani, J. Bohannon, J. Hoeftberger, R. Jacobs, B.M. Wollison, N.A. Patel, M.D. Manam, P. Davineni, M. Meyerson, L.E. MacConaill

Presentation 562/23

 

Session PO.CL02.01 Childhood Cancer Clinical Translational Research

Prohibitin is a prognostic marker of treatment failure and therapeutic target to block chemotherapy resistance in Wilms tumor

M.V. Ortiz, M. Burns, A. Eisenberg, S. Ahmed, L. Gaewsky, G. Bradwin, P. Cifani, A. Henssen, I. Macarthur, M. LaQuaglia, A. Letai, A. Naranjo, S. Gadd, Y. Chi, J. Dome, E. Perlman, E. Mullen, H. Steen, A. Kentsis

Presentation 708/25

 

Session PO.ET06.09 Alternative Small-Molecule Therapies

Suppression of adaptive responses to targeted therapies by transcriptional inhibition

M. Rusan, K. Li, Y. Li, C.L. Christensen, B.J. Abraham, N. Kwiatkowski, K. Buczkowski, B. Bockorny, T. Chen, S. Li, H. Zhang, H. Terai, T. Tavares, T. Zhang, T.J. Kim, M. Silkes, T. Mudianto, L. Tan, T. Shimamura, M. Meyerson, H. Watanabe, N.S. Gray, R.A. Young, K. Wong, P.S. Hammerman

Presentation 15/15

 

Session PO.IM01.01 Tumor Antigens and Adaptive Immunity

Targeting MHC class I molecules and immune checkpoints as key immune evasion strategies in EBV-associated nasopharyngeal carcinoma

S.Siu, K. To, G. Chung, V. Lui, Y.Y. Li, P.S. Hammerman, K.W. Lo.

Presentation 646/20

 

The epigenetic landscape of T cell exhaustion

Debattama Sen

Presentation 654/28

 

Session PO.IM02.02 Checkpoints 1

Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma

D. Miao, D. Liu, D. Keliher, S. Shukla, B. Schilling, C. Margolis, A. Smart, L. Garraway, S. Hodi, D. Schadendorf, E.M. Van Allen

Presentation 571/5

 

Session PO.MCB09.01 Genomic Screening for Cancer Dependencies and Drug Response

Genome engineering to generate models of chromosome arm-level aneuploidies in lung carcinoma

A.M. Taylor, G. Ha, J. Shih, X. Zhang, J.M. Francis, M. Meyerson

Presentation 409/9

 

Defining molecular mechanisms of resistance to glioblastoma immunity using novel CRISPR/Cas9 in vivo loss-of-function screening platform

M.R. Neagu, R.T. Manguso, H.Pope, M.C. Speranza, G.J. Freeman, J.Doench, A.H. Sharpe, W.N. Haining

Presentation 417/17

 

Session PO.MCB09.05 Genomic Analyses across Cancer Types

Saturation mutagenesis of KRAS reveals the functional landscape of missense variants

E. Kim, S. Huong Ly, N.S. Persky, B. Wang, X. Yang, F. Piccioni, K. Labella, M. Doshi, R.E. Lintner, C. Zhu, S. Steelman, D.E. Root, C.M. Johannessen, A.B. Burgin, L.E. MacConaill, W.C. Hahn, A.J. Aguirre

Presentation 394/20

 

Session PO.MCB10.01 MicroRNA Regulation of Cancer Biology 1

Diminished microRNA-29b results in overexpression of BRD4 and BRD4-regulated oncogenes in cutaneous T-cell lymphoma

R. Kohnken, J. Wen, B. Mundy-Bosse, M. Yano, L. Grinshpun, K. McConnell, A. Keiter, A. Hartlage, J. Bradner, M. Caligiuri, P. Porcu, A.Mishra

Presentation 481/22

 

Session PO.TB01.01 Cell Culture and Animal Models of Cancer 1

Loss of function of Arid1a synergizes with MYCN in neuroblastoma pathogenesis 

H. Shi, T. Tao, C. Kadoch, T. Look

Presentation 802/8

Monday, April 3rd 2017

8:00am - 12:00pm

Session PO.BSB01.02 Functional and Genomic Analysis of Cancer

Pan-cancer patterns of synthetic lethality: statistical modeling of gene dependency profiles

H. Yeerna, R. Rangan, A. Aguirre, W. Kim, F. Vazquez, B. Weir, M. Ghandi, A. Tsherniak, J. Boehm, W. Hahn, J. Mesirov, P. Tamayo

Presentation 1555/4

 

A computational framework for removing mouse contamination in tumors sequenced from patient-derived xenografts

A. Amin-Mansour, J.Jané-Valbuena, X.J. Mu, L.Garraway

Presentation 1564/13

 

Session PO.EP01.01 Genome-Wide Association Studies/Post-GWAS Studies

Transcriptome-wide association study of prostate cancer risk

M. Chen, A. Gusev, The PRACTICAL Consortium, M. Loda, L.A. Mucci, M.J. Stampfer, P.Kraft, K.L. Penney

Presentation 1321/22

 

Session PO.EP01.07 Genetic Variation (Non-GWAS) and Cancer Risk, Prognosis, or Mechanisms

Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors

S.H. Zaidi, W. Sun, J. Huyghe, C.S. Grasso, Q. Trinh, C. Connolly, A. French, J. Mu, M. Giannakis, E. Shinbrot, I. Borozan, M.J. Quist, H. Brenner, D.Buchanan, P. Campbell, A. Chan, J. Chang-Claude, V. Ferretti, C. Fuchs, A. Gsur, M. Gunter, T. Harrison, M. Hoffmeister, W. Huang, P. Krzyzanowski, S. Lee, M. Lemire, J. Miller, D. Pasternack, C. Teney, E. Mardis, P. Newcomb, L. Stein, L. Timms, D. Wheeler, C. Yung, N. Zubair, L. Garraway, S. Ogino, L. Hsu, S. Gallinger, S. Thibodeau, T. Hudson, U. Peters

Presentation 1286/17

 

Association of common genetic variants with TMPRSS2 ERG fusion status in prostate cancer

I. Kohaar, L. Ravindranath, D. Young, A. Ali, Q. Li, A. Dobi, D. McLeod, I.L. Rosner, I. Sesterhenn, M. Freedman

Presentation 1290/21

 

Session PO.ET03.01 DNA Repair

Synthetic lethality of CDK12 inhibition in tumors with WES/FLI rearrangements

A.L. Balboni, B. Stolte, A.S. Conway, G. Alexe, E. Jue Wang, N. Kwiatkowski, T. Zhang, B.J. Abraham, P. Kalev, D. Chowdhury, C.H. Benes, R.A. Young, N.S. Gray, K. Stegmaier

Presentation 1118/11

 

Developing kinase inhibitors with polypharmacological profiles for the treatment of resistant cancers

S. Rao, T. Li, R. Everley, G. Du, P. Sorger, N. Gray

Presentation 1222/7

 

Session PO.IM02.08 Tumor Microenvironment and Checkpoints 

CDK4/6 inhibition directly enhances an anti-tumor immune response in breast cancer

M.J. DeCristo, S. Goel, A.C. Watt, H. BrinJones, J. Sceneay, B. Li, J.M. Ubellacker, S. Xie, S. Ramm, H. Kim, S.S. McAllister, J.J. Zhao

Presentation 1634/12

 

Session PO.MCB07.02 Genomic Instability and Cancer Therapy

PCNA-dependent cleavage and degradation of SDE2 regulates response to replication stress

U. Jo, W. Cai, J. Wang, Y. Kwon, A.D. D’Andrea, H. Kim

Presentation 1403/2

 

Targeting cell cycle dependencies in CCNE1 amplified tumors

Presentation 1425/24

 

Session PO.TB08.02 Pediatric Cancer 1: Biomarkers, Preclinical Models, and New Targets

High-throughput chemical screening identifies Focal Adhesion Kinase and Aurora Kinase B inhibition as a synergistic treatment combinations in Ewing sarcoma

B. Crompton, S. Wang, E. Hwang, R. Guha, M. Boxer, C. McKnight, M. Shen, N. Melong, C. Veinotte, A. Conway, J. Berman, M. Hall, M. Davis, K. Stegmaier

Presentation 1943/15

 

Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models

Y.Yi. Tseng, A. Hong, P. Keskula, S. Gill, J. Cheah, G. Kryukov, A. Tsherniak, F. Vazquez, G. Cowley, S. Alkhairy, C. Oh, A. Peng, R. Deasy, A. Sayeed, P. Ronning, S. Ng, S. Corsello, C. Painter, D. Sandak, L. Garraway, M. Rubin, C. Kuo, S. Puram, D. Weinstock, A. Bass, N. Wagle, K. Ligon, K. Janeway, D. Root, S. Schreiber, P. Clemons, A. Shamji, W. Hahn, T. Golub, J. Boehm

Presentation 1953/25

 

LBPO.MCB02 Late-Breaking Research: Molecular and Cellular Biology 2

SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation

X. Wang, R. Lee, B. Alver, J. Haswell, S. Wang, E. Troisi, B. Bernstein, P. Park, C. Roberts

Presentation LB-096/21

Monday, April 3rd 2017

1:00pm - 5:00pm

Session PO.BSB01.03 Computational Tools and Databases

CellMinerCDB: Enabling cross-database exploration of molecular pharmacology data and response determinant discovery in cancer cell lines

V.N. Rajapakse, A. Luna, C. Sander, W.C. Reinhold, Y. Pommier

Presentation 2586/5

 

GenePattern Notebook: An environment for reproducible cancer research

M.M. Reich, T.T. Tabor, T. Liefeld, B. Hill, H. Thorvaldsdottir, J.P. Mesirov

Presentation 2588/7

 

The cBioPortal for Cancer Genomics: An open source platform for accessing and interpreting complex cancer genomics data in the era of precision medicine

J. Gao, E. Ciftci, P. Raman, P. Lukasse, I. Bahceci, A. Abeshouse, H.W. Chen, I. de Bruijn, B. Gross, Z. Heins, R. Kundra, A. Lisman, A. Ochoa, R. Sheridan, O. Sumer, Y. Sun, J. Wang, M. Wilson, H. Zhang, J. Xu, A. Dufilie, P. Kumari, J. Lindsay, A. Cros, K. Kalletla, F. Schaeffer, S. Tan, S. van Hagen, J. Reis-Filho, K. van Bochove, U. Dogrusoz, T. Pugh, A. Resnick, C. Sander, E. Cerami, N. Schultz

 

Global integration of knowledgebases for clinical interpretation of cancer variants

O.L. Griffith, M. Griffith, D. Tamborero, A.H. Wagner, K. Krysiak, C. Del Vecchio Fitz, D. Chakravarty, E. Cerami, O. Elemento, N. Schultz, A. Margolin, N. Lopez-Bigas

Presentation 2608/27

 

Session PO.CL10.12 Predictive Biomarkers 2

Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

B.S. Kochupurakkal, K. Parmar, J.B. Lazaro, C. Unitt, Q. Zeng, H. Reavis, C. Ganesa, S. Zhou, J. Liu, S. Palakurthi, K. Strickland, B. Howitt, P. Konstantinopoulos, P. Kirschmeier, J. Geradts, R. Drapkin, U. Matulonis, A. D'Andrea, G. Shapiro

Presentation 2796/28

 

Session PO.ET03.02 Cell Death Targets

PDE3A modulation for cancer therapy

X. Wu, T. Lewis, L. de Waal, G. Gao, J. Zhang, M. Schenone, C. Garvie, B. Diamond, S. Lorrey, A. Cherniack, S. Corsello, A. Burgin, T. Golub, S. Schreiber, M. Meyerson, H. Greulich

Presentation 2028/13

 

Session PO.ET06.07 Growth Factor and Hormone Receptors as Therapeutic Targets

Conformational activation and allosteric inhibition of SHP2 in RTK-driven cancers

M.G. Acker, Y.P. Chen, M.J. LaMarche, H.M. Chan, P. Fekkes, J. Garcia-Fortanet, J.R. LaRochelle, B. Antonakos, C. Hiu-Tung Chen, Z. Chen, V.G. Cooke, J.R. Dobson, Z. Deng, F. Feng, B. Firestone, M. Fodor, C. Fridrich, H. Gao, H.X. Hao, J. Jacob, S. Ho, K. Hsiao, Z.B. Kang, R. Karki, M. Kato, J. Larrow, L.R. La Bonte, G. Liu, S. Liu, D. Majumdar, M.J. Meyer, M. Palermo, M. Pu, E. Price, S. Shakya, M.D. Shultz, K. Venkatesan, P. Wang, M. Warmuth, S. Williams, G. Yang, J. Yuan, J.H. Zhang, P. Zhu, S.C. Blacklow, T. Ramsey, N.J. Keen, W.R. Sellers, T. Stams, P.D. Fortin

Presentation 2084/11

 

Session PO.MCB02.01 Apoptosis and Other Regulated Cell Death in Cancer

A high-throughput screen identified cancer selective small molecules that kill independent of mitochondrial apoptosis

C.M. Dowling, M. Hemann, J. Bradner, A. Letai, T. Ni Chonghaile

Presentation 2326/20

 

Session PO.MBC04.02 Genome-Wide Analysis of Transcriptional Regulation

Large scale integrated transcriptomic and epigenetic profiling defines the molecular hallmarks of HGSOC and disease origins

K. Lawrenson, M. Abraao, F. Segato, J.M. Lee, S. Coetzee, J.H. Seo, M.L. Freedman, D. Hazelett, S. Gayther, H. Noushmehr

Presentation 2417/4

 

Session PO.MCB08.03 Metabolomics and Metabolic Regulation

Amine and lipid metabolites are enriched in advanced prostate cancer

L.A. Mucci, E. Ebot, C. Clish, S. Markt, R. Taylor, M. Watt, P. Kantoff, E. Giovanucci, M. Vander Heiden, K. Wilson

Presentation 2498/4

 

Session PO.MCB09.03 Genomic Landscape of Lymphoma, Leukemia, and Lung, Bladder, and Other Cancers

Transcriptome and whole-genome sequencing analysis of a novel murine model of chronic lymphocytic leukemia

L. Wang, J. Sun, A. Taylor-Weiner, J. Kim, Z.J. Cartun, A.N. Brooks, D. Neuberg, M.D. Fleming, B.L. Ebert, G.Getz, R.Carrasco, C.J. Wu

Presentation 2449/6

 

Session PO.TB11.01 Tumor Evolution and Heterogeneity 1

Clinical and genomic resistance to second generation androgen blockade in paired biopsies of metastatic castration-resistant prostate cancer 

G. Celine Han, J. Hwang, S.A. Mullane, C. Cibulskis, Z. Zhang, R.R. McKay, PCF-SU2C Dream Team, S.L. Carter, W.C. Hahn, M.E. Taplin, E. Van Allen

Presentation 2905/1

 

Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature

D. Liu, D. Keliher, P. Abbosh, K. Mouw, D. Miao, M. Boyd, J. Hoffman-Censits, G. Iyer, S. Tolaney, J. Kim, G. Getz, S. Carter, J. Bellmunt, E.R. Plimack, J.E. Rosenberg, E. Van Allen

Presentation 2918/14

 

Session LBPO.ET01 Late-Breaking Research: Experimental and Molecular Therapeutics 1

Characterization of lineage vs. context-dependent essential genes in multiple myeloma using CRISPR-Cas9 genome editing

G.M. Matthews, R. de Matos Simoes, Y. Hu, M. Sheffer, O. Dashevsky, E. Dhimolea, P.J. Hengeveld, B.J. Glassner, S. Gandolfi, M.A. Bariteau, Q. Sievers, B.L. Ebert, F. Vazquez, A. Culhane, C.S. Mitsiades

Presentation LB-118/10

 

Session PO.CT02 Phase III Clinical Trials and Phase II/III Clinical Trials in Progress

Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

T.J. Kipps, G. Fraser, S. Coutre, J.R. Brown, J.C. Barrientos, P.M. Barr, J.C. Byrd, S.M. O'Brien, M.S. Dilhuydy, S. Devereux, U. Jaeger, C. Moreno, P. Cramer, S. Stilgenbauer, A.A. Chanan-Khan, M. Mahler, M. Salman, M. Cheng, A. Londhe, J. Ninomoto, A. Howes, D. James, M. Hallek

Presentation CT158/24

Tuesday, April 4th 2017

8:00am - 12:00pm

Session PO.BSB01.04 Sequencing Analysis and Algorithms

The long tail of significantly mutated genes in prostate cancer

J. Armenia, S. Mullane, J. Gao, D. Chakravarty, R. Kundra, F. Huang, C. Han, D. Robinson, L.  Garraway, P. Nelson, M. Rubin, M.E. Taplin, W. Abida, C.L. Sawyers, A.M. Chinnaiyan, P.W. Kantoff, J.S. Bono, N. Schultz, E. Van Allen

Presentation 3566/2

 

GATK CNV: copy-number variation discovery from coverage data

M. Babadi, D. Benjamin, S. Lee, A. Smirnov, A. Chevalier, L. Lichtenstein, V. Ruano Rubio

Presentation 3580/16

 

GATK ACNV: allelic copy-number variation discovery from SNPs and coverage data

A. Chevalier, L. Lichtenstein, A. Smirnov, S. Lee, M. Babidi, D. Benjamin, V. Ruano-Rubio

Presentation 3581/17

 

Somatic variation discovery with GATK4

G.A. Van der Auwera

Presentation 3590/26

 

Session PO.EN01.02 Nuclear Receptors and Endocrine Oncology Therapies

Validation of PPARG and RXRA as drivers of bladder cancer

J. Goldstein, C. Strathdee, F. Duke, J. Shih, Ma. Meyerson

Presentation 3627/26

 

Session PO.EP01.10 Survivorship Research

Association of low-carbohydrate diet and macronutrient intake with colorectal cancer survival

M. Song, K. Wu, J. Meyerhardt, O. Yilmaz, S. Ogino, C. Fuchs, E. Giovannucci, A. Chan

Presentation 3270/3

 

Session PO.ET01.04 Differentiation Therapy

Inhibitors of the enzyme dihydroorotate dehydrogenase, overcome the differentiation blockade in acute myeloid leukemia

A. Janzer, D. Sykes, S. Gradl, S. Ferrara, S. Christian, C. Merz, H. Seidel, A. Bernthaler, R. Lesche, M. Wawer, D. Scadden

Presentation 3038/3

 

Session PO.ET04.03 Novel Mechanisms 1

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple-negative breast cancer patients

S. Kabraji, X. Sole, Y. Huang, C. Bango, M. Bowden, A. Bardia, D. Sgroi, M. Loda, S. Ramaswamy

Presentation 3173/4

 

Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis

V. Wang, J. Doench, D. Root, R. Bernards, J. Settleman, F. McCormick

Presentation 3182/13

 

Session PO.IM02.07 Dendritic Cells as Critical Immune Targets 

Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer

D. Adeegbe, Y. Liu, P. Lizotte, Y. Kamihara, M. Awad, D. Barbie, J. Ritz, S. Jones, S. Quayle, P. Hammerman, K.K. Wong

Presentation 3682/25

 

Session PO.MCB04.03 Oncogenic Transcription Factors

LHX9 is a novel oncogene bypassing KRAS

S.H. Ly, C. Dai, A.L. Hong, N. Ilic, E.B. Krall, W.C. Hahn

Presentation 3515/8

 

TGF-β pathway alteration in pancreatic neuroendocrine tumors: characterization of a novel SMAD3 translocation

E. Brunetto, G. Grassini, V. De Pascali, A. Talarico, F. Invernizzi, M. Bowden, M. Loda, L. Albarello, M. Falconi, L. Pecciarini, M.G. Cangi, C. Doglioni

Presentation 3519/12

 

Session PO.PR02.01 Strategies and Biomarkers for Clinical Prevention

The genomic landscape of premalignant lung squamous cell carcinoma lesions

J. Campbell, X. Zhang, S. Dhillon, C. Perdomo, S. Mazzilli, Y. Geshalter, G. Liu, S. Zhang, Ha. Lin, J. Vick, C. Moy, S. Monti, E. Johnson, M. Meyerson, S. Dubinett, S. Platero, M. Wilkerson, C. Dalgard, M. Lenburg, M. Reid, J. Beane, A. Spira

Presentation 3259/5

 

Session PO.TB01.04 Cell Culture and Animal Models of Cancer 4

Targeting HER2 in gastric cancer: Hints from a gastric PDX platform

S. Corso, C. Migliore, M. Apicella, S. Menegon, E. Pectasides, T. Capeloa, S. Durando, M. Cargnelutti, P. Cassoni, A. Sapino, M. de Giuli, A. Bass, S. Giordano

Presentation 3851/17

 

Session PO.TB02.04 Targeting Cancer Stem Cells

Inhibition of the ERK5 pathway as a novel approach to target human chronic myeloid leukemia stem cells

I. Tusa, G. Cheloni, N. Gray, A. Gozzini, P. Dello Sbarba, E. Rovida

Presentation 3904/27

 

Session PO.TB06.05 Tumor Microenvironment 5

Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids

D. Barbie, R. Jenkins, K.K. Wong

Presentation 3972/15

 

Immune correlates of pathologic response in bladder cancer patients undergoing neoadjuvant chemotherapy

P. Abbosh, D. Liu, W. Choi, W. El-Deiry, J. Rosenberg, D. McConkey, E. Plimack, E. Van Allen

Presentation 3979/22

 

Session PO.TB08.03 Pediatric Cancer 2: Epigenetics and Stem Cells

SSX drives gain-of-function BAF complex chromatin affinity and genomic targeting in synovial sarcoma

M. McBride, J. Pulice, R. Nakayama, N. Mashtalir, D. Ingram, J. Shern, J. Khan, J. Hornick, A. Lazar, C. Kadoch

Presentation 3875/13

 

Session LBPO.TB02 Late-Breaking Research: Tumor Biology 2

Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids

E. Ivanova, A. Aref, R. Jenkins, P. Lizotte, W. Huang, S. Palakurthi, P. Kirschmeier, D. Barbie, C. Paweletz, P. Janne, K.K. Wong

Presentation LB-218/13

 

Identifying cancer-related processes in normal tissues via RNA-seq

K. Yizhak, J. Kim, F. Aguet, J. Hess, H. Zhang, E. Arich-Landkof, N. Shoresh, A. Segre, C. Stewart, D. Rosebrock, D. Livitz, N. Haradhvala, P. Polak, T. Sullivan, X. Li, K. Ardlie, G. Getz

Presentation LB-231/26

 

Session LBPO.IM01 late-Breaking Research: Immunology

Next-generation epitope prediction using mass spectrometry and integrative genomics

M. Rooney, J. Abelin, S. Sarkizova, D. Keskin, C. Hartigan, W. Zhang, J. Sidney, W. Lane, J. Stevens, G. Zhang, K. Clauser, N. Hacohen, S. Carr, C. Wu

Presentation LB-179

Tuesday, April 4th 2017

1:00pm - 5:00pm

Session PO.EP01.05 Biomarkers of Endogenous or Exogenous Exposures, Early Detection, and Biologic Effects

Consortium for METabolomics Studies (COMETS): leveraging resources to accelerate scientific discovery

R. Stolzenberg-Solomon, S. Moore, C. Ulrich, E. Poole, M. Temprosa, M. Verma, D. Albanes, C. Barrios Barrera, E. Boerwinkle, J.P. Casas, C. Clish, R. Gerszten, C. Gieger, M. Gunter, S. Harada, T. Harris, D. Herrington, A. Hsing, M. Johannson, C. Langenberg, J. Lasky-Su, L. Le Marchand, C. Matthews, C. Menni, M. Oresic, E. Orwoll, A. Pereira, K. Rexrode, S. Shah, X. Shu, V. Stevens, B. Yu, H. Zhao, K. Zanetti

Presentation 4238/4

 

Session PO.EP01.06 Familial and Hereditary Cancers

Mutations in RABL3 alter RAS prenylation and are associated with hereditary pancreatic cancer

S. Nissim, I. Leshchiner, J. Mancias, M. Greenblatt, O. Maertens, C. Cassa, J. Rosenfeld, A. Cox, J. Hedgepeth, J. Wücherpfennig, A. Kim, J. Henderson, P. Gonyo, A. Brandt, E. Lorimer, B. Unger, J.W. Prokop, J. Heidel, X. Wang, C. Ukaegbu, G. Getz, S. Sunyaev, J. Wade Harper, K. Cichowski, A. Kimmelman, Y. Houvras, S. Syngal, C. Williams, W. Goessling

Presentation 4272/8

 

Session PO.ET01.06 Assay Technology

Accelerating drug repurposing for cancer therapy using multiplexed viability assays

S. Corsello, C. Mader, J. Bryan, J. Roth, D. Peck, J. Davis, S. Bender, L. Wang, A. Wang, J. Bittker, F. Vazquez, A. Subramanian, A. Tsherniak, T. Golub

Presentation 4025/15

 

Session PO.ET04.07 Molecular Targeted Therapies 2

Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients

L. Goyal, S. Saha, L. Liu, G. Siravegna, I. Leshchiner, L. Ahronian, J. Lennerz, P. Vu, B. Mussolin, S. Reyes, P. Furet, A. John Iafrate, G. Getz, D. Porta, R. Tiedt, A. Bardelli, D. Juric, R. Corcoran, N. Bardeesy, A. Zhu

Presentation 4114/24

 

Session PO.ET06.02 Combination Therapies and approaches to Sensitize Cancer Cells to Drugs

Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer

L. Iavarone, I. Zervantonakis, L. Selfors, S. Palakurthi, J. Liu, U. Matulonis, R. Drapkin, G. Mills, J. Leverson, D. Sampath, J. Brugge

Presentation 4033/3

 

 Session PO.ET06.06 Targeting Protein Kinases and DNA Repair

Homologous recombination pathway-based biomarkers for treatment of non-small cell lung cancer with PARP inhibitors

P. Deraska, H. Reavis, S. Labe, A. D'Andrea, D. Kozono

Presentation 4189/12

 

Session PO.IM01.02 Innate Immune Response to Cancer

Exploring the role of interferon and innate immune regulators in outlier cancer cell line survival

H. Gannon Jr., M. Kiessling, F. Vazquez, W. Hahn, M. Meyerson

Presentation 4616/1

 

Session PO.IM02.09 Clinical Immunotherapy, Viruses, and Bacteria

Fusobacterium nucleatum and tumor immunity status according to microsatellite instability in colorectal cancer

K. Mima, T. Hamada, R. Nishihara, J. Nowak, Z. Rong Qian, K. Kosumi, M. Giannakis, S. Bullman, H. Baba, C. Huttenhower, W. Garrett, A. Chan, M. Meyerson, C. Fuchs, S. Ogino

Presentation 4560/5

 

Session PO.TB08.04 Pediatric Cancer 3: Genetics and Genomics

Gene fusion detection in pediatric tumor samples utilizing multi-caller fusion detection approach and integrative data analysis

A. Imamovic, M. Harris, A. Church, B. Crompton, E. Van Allen, K. Janeway

Presentation 4872/6

 

Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors

A. Henssen, R. Koche, J. Zhuang, E. Jiang, C. Reed, A. Eisenberg, E. Still, E. Rodríguez-Fos, S. Gonzalez, M. Puiggròs, A. Blackford, C. Mason, E. de Stanchina, M. Gönen, A. Emde, M. Shah, K. Arora, C. Reeves, N.D. Socci, E. Perlman, C. Antonescu, C. Roberts, H. Steen, E. Mullen, S. Jackson, D. Torrents, Z. Weng, S. Armstrong, A. Kentsis

Presentation 4888/22

 

Session LBPO.MCB03 Late-Breaking Research: Molecular and Cellular Biology 3

The landscape of somatic rearrangements across 2783 cancer whole-genomes

O. Shapira, J. Wala, J. Weischenfeldt, Y. Li, S. Schumacher, N. Roberts, C. Zhang, D.Craft, X. Yao, C. Stewart, E. Rheinbay, G. Saksena, J. Tubio, M. Meyerson, J. Korbel, M. Imielinski, G. Getz, P. Campbell, R. Beroukhim

Presentation LB-279/18

 

The landscape of somatic microsatellite indels across cancer: detection and identification of driver events

Y. Maruvka, K. Mouw, R. Karlic, R. Parasuraman, A. Kamburov, P. Polak, N. Haradhvala, J. Hess, E. Rheinbay, Y. Brody, L. Braunstein, A. D’Andrea, M. Lawrence, A. Bass, A. Bernards, F. Michor, G. Getz

Presentation LB-280/19

Wednesday, April 5th 2017

8:00am - 12:00pm

Session PO.MCB09.08 Genomic Analyses of Circulating Tumor Material and RNA

Broad Genomics and Cancer Program development of comprehensive blood biopsy sequencing capabilities to support direct-to-patient cancer research initiatives

C. Cibulskis

Presentation 5390/1

 

Session PO.BSB02.01 Systems Biology Approaches to Cancer Diagnostics and Disease Management

Using cancer dependency data to discover tumor suppressive and oncogenic functional modules

J. Pan, R. Meyers, B. Michel, A. Sizemore, F. Vazquez, B. Weir, W. Hahn, A. Tsherniak, C. Kadoch

Presentation 5559/17

 

Single-cell analysis reveals an adaptive, transiently heritable, slowly-dividing, drug-resistant state inhibitable by drug combinations

M. Fallahi-Sichani, V. Becker, B. Izar, G. Baker, J. Lin, S. Boswell, L. Garraway, P. Sorger

Presentation 5561/19

 

A scalable and integrated computational and experimental workflow to identify new driver genes in cancer genome data

H. Horn, M. Lawrence, C. Chouinard, Y. Shrestha, J. Xin Hu, E. Worstell, E. Shea, N. Ilic, E. Kim, A. Kamburov, A. Kashani, W. Hahn, J. Campbell, J. Boehm, G. Getz, K. Lage

Presentation 5567/25

 

Session PO.CL.10.09 Liquid Biopsies 5: cfDNA, MicroDNA, and Protein

Identify tissue-of-origin in cancer cfDNA by whole genome sequencing

Y. Liu, S. Reed, A. Choudhury, H. Parsons, D. Stover, G. Ha, G. Gydush, J. Rhoades, D. Rotem, S. Freeman, V. Adalsteinsson, M. Kellis

 Presentation 5689/13

 

Increased sensitivity for detection of oncogenic mutations present in circulating cell-free tumor DNA

A. Thorner, M. Slevin, A. Clapp, H. Coleman, S. McShane, S. Drinan, E. Thai, B. Wollison, R. Burns, A. Frieden, M. Ducar, A. Nag, L. MacConaill, M. Meyerson

 

Session PO.CL06.02 Innate Immunity to Generate Adaptive Immunity

Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy

A. Smart, C. Margolis, D. Miao, D. Liu, J. Park, M. Xiao He, B. Reardon, S. Mullane, B. Schilling, L. Garraway, D. Schadendorf, E. Van Allen

Presentation 5647/1

 

Session PO.ET06.03 Novel Chemotherapies

A novel nucleoside analog therapeutically active against plasma cell malignancies and other ADK-expressing cancers including colon and pancreatic adenocarcinomas

J. Sadek, U. Nayar, J. Reichel, J. Totonchy, S. Sei, R. Shoemaker, D. Warren, O. Elemento, K. Kaye, E. Cesarman

Presentation 5110/12

 

Session PO.MCB04.05 Regulation of Oncogenic Transcription

Non-overlapping promoter and super-enhancer-associated dependencies in multiple myeloma

M. Fulciniti, C. Lin, M. Samur, R. Young, H. Avet-loiseau, K. Anderson, J. Bradner, N. Munshi

Presentation 5490/4

 

Identification of super-enhancer-associated cancer genes provides novel therapeutic targets in adult T-cell leukemia/lymphoma

T. Sanda, R. Wong, P. Cao, W. Leong, A. Yam, T. Zhang, S. Iida, T. Okamoto, R. Ueda, N. Gray, T. Ishida

Presentation 5487/1

 

Session LBPO.ET02 Late-Breaking Research: Experimental and Molecular Therapeutics 2

Substrate-mimetic covalent inhibitor of MALT1 is most effective against CARD11 mutant ABC-DLBCL

L. Fontan, D. Scott, J. Hatcher, Q. Qiao, I. Us, G. Casalena, M. Bekkers, U. Philippar, M. Durant, S. Chennamadhavuni, H. Wu, N. Gray, A. Melnick

Presentation LB-303/11